Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Actinium Pharmaceuticals (ATNM) Assets (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Assets for 7 consecutive years, with $82.1 million as the latest value for Q3 2024.

  • On a quarterly basis, Assets fell 7.68% to $82.1 million in Q3 2024 year-over-year; TTM through Sep 2024 was $82.1 million, a 7.68% decrease, with the full-year FY2023 number at $81.4 million, down 28.68% from a year prior.
  • Assets was $82.1 million for Q3 2024 at Actinium Pharmaceuticals, down from $89.9 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $121.8 million in Q2 2022 to a low of $74.6 million in Q1 2022.
  • A 4-year average of $92.2 million and a median of $88.4 million in 2024 define the central range for Assets.
  • Peak YoY movement for Assets: soared 44.22% in 2022, then decreased 28.68% in 2023.
  • Actinium Pharmaceuticals' Assets stood at $80.4 million in 2021, then soared by 42.05% to $114.2 million in 2022, then dropped by 28.68% to $81.4 million in 2023, then grew by 0.82% to $82.1 million in 2024.
  • Per Business Quant, the three most recent readings for ATNM's Assets are $82.1 million (Q3 2024), $89.9 million (Q2 2024), and $88.4 million (Q1 2024).